查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美生物製藥市場預測至 2028 年 - 區域分析 - 按產品類型和應用
市場調查報告書
商品編碼
1360047

北美生物製藥市場預測至 2028 年 - 區域分析 - 按產品類型和應用

North America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type and Application
出版日期: | 出版商: The Insight Partners | 英文 224 Pages | 訂單完成後即時交付

價格

2022年北美生物製藥市場估值為1,512.2億美元，預計到2028年將達到3,157.4億美元。預計2022年至2028年年複合成長率為13.1%。

治療罕見疾病的潛力推動北美生物製藥市場

根據美國國立衛生研究院 (NIH) 的報告，有 3,000 萬美國人（佔總人口的 10%）患有約 7,000 種已知罕見疾病之一。開發治療這些罕見疾病的藥物面臨科學和操作上的挑戰。與罕見疾病相關的複雜生物學為科學家設計和實施新藥開發計畫帶來了挑戰。然而，儘管面臨這些挑戰，北美的生物製藥研究人員仍然開發了治療罕見疾病的新技術並開發了突破性的療法。此外，在過去十年中，美國 FDA 批准了 350 種孤兒藥，特別是針對缺乏治療或治療選擇有限的疾病。轉甲狀腺素蛋白澱粉樣心肌病變 (ATTR-CM) 是一種危及生命的進行性心血管罕見疾病，其特徵是心臟功能異常，導致浸潤性心肌病變。一旦確診，如果不及時治療，中位數預期壽命僅為 2.5-3.5 年。此外，生物製藥公司 Ultragenyx Pharmaceutical Inc. 致力於治療 3 型糖原貯積症 (GSD) 這種嚴重罕見的超遺傳性疾病的分子的安全性測試和劑量確定。該公司於2021年12月啟動了UX053的臨床研究，將其作為第一個治療GSD3患者的潛在藥物推出。 UX053 mRNA 可以將大基因遞送至目標細胞，以實現蛋白質表現的高度一致性。該公司計劃根據每位患者的需求，透過調整劑量水平和頻率來個性化 mRNA 療法。此類臨床開發、上市和批准正在加速北美生物製藥市場的擴張。

北美生物製藥市場概況

北美生物製藥市場分為美國、加拿大和墨西哥。該地區的市場成長歸因於癌症發生率的增加、該地區產品引進的增加以及生物製藥技術的進步。生物製藥產業正處於醫學研究的關鍵階段，具有進一步徹底改變阿茲海默症、癌症、心臟病和丙型肝炎等昂貴且衰弱性疾病的治療的巨大潛力。慢性病負擔不斷增加，研發投資不斷增加美國的活動正在推動該地區的市場。生物製藥產業對美國經濟做出了重要貢獻。美國在大多數研發投資和創新指數方面領先世界。截至2020年，美國生物製藥公司有超過3,400種藥物處於臨床開發階段，幾乎佔全球估計8,000種藥物的一半（其中1,100種正在開發用於治療各種類型的癌症）。生物製藥產業透過創造直接經濟活動和支持間接經濟活動，為美國經濟做出了重要貢獻。 2018年，製藥和醫療製造業佔私部門增加價值的0.95%。生技研發設施又佔0.23%。美國疾病管制與預防中心 (CDC) 於 2022 年 7 月更新的數據顯示，冠狀動脈疾病是最常見的心臟病。在美國，大約有 2010 萬 20 歲及以上的成年人患有這種疾病。根據CDC資料，每40秒就有一人心臟病發作，美國每年有近80.5萬人心臟病發作。所有這些因素預計將在預測期內顯著推動北美生物製藥市場的成長。

北美生物製藥市場收入及 2028 年預測（十億美元）

北美生物製藥市場細分

北美生物製藥市場按產品類型、應用和國家細分。

根據產品類型，北美生物製藥市場分為單株抗體、重組疫苗、常規疫苗、重組生長因子、純化蛋白、重組蛋白、重組激素、重組酶、細胞和基因療法、細胞激素/干擾素/白血球介素和其他。 2022年，單株抗體領域佔據北美生物製藥市場的最大佔有率。

重組疫苗細分為癌症疫苗、瘧疾疫苗、伊波拉疫苗、B型肝炎疫苗、破傷風疫苗、白喉疫苗、霍亂疫苗等。傳統疫苗細分為小兒麻痺疫苗、痘疫苗等。重組生長因子片段進一步細分為紅血球生成素和粒細胞集落刺激因子。純化的蛋白質片段進一步細分為白血病抑制因子（LIF）、P53蛋白、P38蛋白等。重組蛋白片段進一步分為血清白蛋白、澱粉樣蛋白、防禦素和轉鐵蛋白。重組激素細分為重組人生長激素、重組胰島素和其他重組激素。重組酶片段進一步分為腸激酶、環化酶、半胱天冬酶和組織蛋白酶。細胞和基因治療領域進一步細分為同種異體產品、自體產品和非細胞產品。

根據應用，北美生物製藥市場分為腫瘤學、發炎和傳染病、自體免疫疾病、代謝障礙、荷爾蒙失調和生長障礙、心血管疾病、神經系統疾病等。 2022年，腫瘤學領域佔據北美生物製藥市場的最大佔有率。

按國家/地區分類，北美生物製藥市場分為美國、加拿大和墨西哥。 2022年，美國佔據北美生物製藥市場最大佔有率。

艾伯維公司、AGC Biologics AS、安進公司、勃林格殷格翰國際有限公司、百時美施貴寶公司、禮來公司、強生公司、龍沙集團、賽默飛世爾科技公司和藥明生物公司是在該領域營運的領先公司。北美生物製藥市場。

目錄

第 1 章：簡介

  • 研究範圍
  • Insight Partners 研究報告指南
  • 市場區隔
    • 北美生物製藥市場 - 按產品類型
    • 北美生物製藥市場 - 按應用
    • 北美生物製藥市場 - 按國家分類

第 2 章：北美生物製藥市場 - 要點

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美生物製藥市場 - 市場格局

  • 概述
  • 北美 PEST 分析
  • 專家意見

第 5 章：北美生物製藥市場 - 主要市場動態

  • 市場促進因素
    • 在癌症治療的應用不斷增加
    • 治療罕見疾病的潛力
  • 市場限制
    • 製造基礎設施成本高昂
  • 市場機會
    • 加速臨床試驗
  • 未來的趨勢
    • 生物製藥合約製造
  • 影響分析

第 6 章：生物製藥市場 - 北美分析

  • 北美生物製藥市場收入預測與分析

第 7 章：北美生物製藥市場 - 2028 年收入和預測 - 按產品類型

  • 概述
  • 2021 年和 2028 年北美生物製藥市場收入佔有率（按產品類型分類）（%）
  • 單株抗體
  • 重組疫苗
  • 常規疫苗
  • 重組生長因子
  • 純化蛋白質
  • 重組蛋白
  • 重組激素
  • 重組酵素
  • 細胞和基因療法
  • 細胞激素/干擾素/白血球介素
  • 其他（基於 mRNA 的療法等）

第 8 章：2028 年北美生物製藥市場分析與預測 -按應用

  • 概述
  • 北美生物製藥市場，按應用分類 2021 年和 2028 年 (%)
  • 腫瘤學
  • 發炎和傳染病
  • 自體免疫疾病
  • 代謝紊亂
  • 荷爾蒙失調與生長障礙
  • 心血管疾病
  • 神經系統疾病
  • 其他治療應用

第 9 章：北美生物製藥市場 - 2028 年收入與預測 - 國家分析

    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥

第 10 章：北美生物製藥市場 - 產業格局

  • 概述
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 11 章：公司簡介

  • Amgen Inc
  • AbbVie Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Thermo Fisher Scientific Inc
  • AGC Biologics AS
  • Lonza Group AG
  • WuXi Biologics Inc

第 12 章：附錄

  • 關於 Insight Partners
  • 專業術語
Product Code: BMIRE00028630

The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022 and is expected to reach US$ 315.74 billion by 2028. It is estimated to register a CAGR of 13.1% from 2022 to 2028.

Potential to Treat Rare Diseases Drives North America Biopharmaceuticals Market

According to the National Institute of Health (NIH) report, 30 million Americans, accounting for 10% of the population, have one of the ~7,000 known rare diseases. Developing medicines for treating these rare diseases presents both scientific and operational challenges. Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceutical researchers in the North America have developed new technologies for treating rare diseases and developing groundbreaking therapies. Moreover, in the last decade, 350 orphan drugs have been approved by USFDA, particularly for conditions lacking treatment or having limited treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive cardiovascular rare disease characterized by the abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once diagnosed, the median life expectancy is only ~2.5-3.5 years if left untreated. Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression. The company plans to individualize mRNA therapies based on the needs of each patient through the adjustment of dose levels and frequency. Such clinical developments, launches, and approvals are accelerating the North America biopharmaceuticals market expansion.

North America Biopharmaceuticals Market Overview

The North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing incidence of cancer, growing product introduction in the region, and technological advancements in biopharmaceuticals. The biopharmaceuticals industry is at a pivotal stage in medical research with tremendous potential to further revolutionize the treatment of costly and debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis C. The rising burden of chronic diseases and increased investment in research and development activities in the US are driving the market in the region. The biopharmaceuticals industry makes important contributions to the US economy. The US leads the world in most R&D investment and innovation indices. As of 2020, biopharmaceutical companies in the United States have more than 3,400 drugs in clinical development, accounting for almost half of the estimated 8,000 drugs worldwide (of which 1,100 are being developed to treat various types of cancer). The biopharmaceuticals industry makes important contributions to the US economy by creating direct economic activities and supporting indirect activities. Pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added in 2018. Biotech R&D facilities accounted for another 0.23%. Data from the Centers for Disease Control and Prevention (CDC), updated in July 2022, shows that coronary artery disease is the most common form of heart disease. Approximately 20.1 million adults aged 20 and older in the United States suffer from this condition. According to CDC data, someone suffers a heart attack every 40 seconds, and nearly 805,000 people in the US suffer a heart attack annually. All these factors are expected to boost the North America biopharmaceuticals market growth significantly during the forecast period.

North America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

North America Biopharmaceuticals Market Segmentation

The North America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the North America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the North America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the North America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the North America biopharmaceuticals market.

Based on country, the North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. In 2022, the US accounted for the largest share of the North America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are the leading companies operating in the North America biopharmaceuticals market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America biopharmaceutical market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the North America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
  • develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Biopharmaceuticals Market - by Product Type
    • 1.3.2 North America Biopharmaceuticals Market - by Application
    • 1.3.3 North America Biopharmaceuticals Market - by Country

2. North America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Biopharmaceuticals Market - Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis
  • 4.3 Expert's Opinion

5. North America Biopharmaceuticals Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Application in Cancer Therapeutics
    • 5.1.2 Potential to Treat Rare Diseases
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Manufacturing Infrastructure
  • 5.3 Market Opportunities
    • 5.3.1 Accelerated Clinical Trials
  • 5.4 Future Trends
    • 5.4.1 Contract Manufacturing of Biopharmaceuticals
  • 5.5 Impact Analysis

6. Biopharmaceuticals Market - North America Analysis

  • 6.1 North America Biopharmaceuticals Market Revenue Forecast and Analysis

7. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • 7.3 Monoclonal Antibodies
    • 7.3.1 Overview
    • 7.3.2 Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Recombinant Vaccines
    • 7.4.1 Overview
    • 7.4.2 Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.1 Cancer Vaccine
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.2 Malaria Vaccine
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.3 Ebola Vaccine
        • 7.4.2.3.1 Overview
        • 7.4.2.3.2 Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.4 Hepatitis-B Vaccine
        • 7.4.2.4.1 Overview
        • 7.4.2.4.2 Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.5 Tetanus Vaccine
        • 7.4.2.5.1 Overview
        • 7.4.2.5.2 Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.6 Diphtheria Vaccine
        • 7.4.2.6.1 Overview
        • 7.4.2.6.2 Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.7 Cholera Vaccine
        • 7.4.2.7.1 Overview
        • 7.4.2.7.2 Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.8 Others
        • 7.4.2.8.1 Overview
        • 7.4.2.8.2 Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Conventional Vaccines
    • 7.5.1 Overview
    • 7.5.2 Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.1 Polio Vaccine
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.2 Pox Vaccine
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.3 Other Conventional Vaccine
        • 7.5.2.3.1 Overview
        • 7.5.2.3.2 Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Recombinant Growth Factors
    • 7.6.1 Overview
    • 7.6.2 Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.1 Erythropoietin
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.2 Granulocyte Colony Stimulating Factor
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Purified Proteins
    • 7.7.1 Overview
    • 7.7.2 Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
        • 7.7.2.1.1 Overview
        • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.2 P53 Protein
        • 7.7.2.2.1 Overview
        • 7.7.2.2.2 P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.3 P38 Protein
        • 7.7.2.3.1 Overview
        • 7.7.2.3.2 P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.4 Other Purified Proteins
        • 7.7.2.4.1 Overview
        • 7.7.2.4.2 Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.8 Recombinant Proteins
    • 7.8.1 Overview
    • 7.8.2 Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.1 Serum Albumin
        • 7.8.2.1.1 Overview
        • 7.8.2.1.2 Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.2 Amyloid Protein
        • 7.8.2.2.1 Overview
        • 7.8.2.2.2 Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.3 Defensin
        • 7.8.2.3.1 Overview
        • 7.8.2.3.2 Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.4 Transferrin
        • 7.8.2.4.1 Overview
        • 7.8.2.4.2 Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.9 Recombinant Hormones
    • 7.9.1 Overview
    • 7.9.2 Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.1 Recombinant Human Growth Hormones
        • 7.9.2.1.1 Overview
        • 7.9.2.1.2 Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.2 Recombinant Insulin
        • 7.9.2.2.1 Overview
        • 7.9.2.2.2 Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.3 Other Recombinant Hormones
        • 7.9.2.3.1 Overview
        • 7.9.2.3.2 Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.10 Recombinant Enzymes
    • 7.10.1 Overview
    • 7.10.2 Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.1 Enterokinase
        • 7.10.2.1.1 Overview
        • 7.10.2.1.2 Enterokinase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.2 Cyclase
        • 7.10.2.2.1 Overview
        • 7.10.2.2.2 Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.3 Caspase
        • 7.10.2.3.1 Overview
        • 7.10.2.3.2 Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.4 Cathepsin
        • 7.10.2.4.1 Overview
        • 7.10.2.4.2 Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.11 Cell and Gene Therapies
    • 7.11.1 Overview
    • 7.11.2 Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.1 Allogenic Products
        • 7.11.2.1.1 Overview
        • 7.11.2.1.2 Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.2 Autologous Products
        • 7.11.2.2.1 Overview
        • 7.11.2.2.2 Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.3 Acellular Products
        • 7.11.2.3.1 Overview
        • 7.11.2.3.2 Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.12 Cytokines/Interferon/Interleukins
    • 7.12.1 Overview
    • 7.12.2 Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.13 Others (mRNA Based Therapeutics, etc.)
    • 7.13.1 Overview
    • 7.13.2 Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

  • 8.1 Overview
  • 8.2 North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Inflammatory and Infectious Diseases
    • 8.4.1 Overview
    • 8.4.2 Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Autoimmune Disorders
    • 8.5.1 Overview
    • 8.5.2 Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Metabolic Disorders
    • 8.6.1 Overview
    • 8.6.2 Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Hormonal Disorders and Growth Failure
    • 8.7.1 Overview
    • 8.7.2 Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Cardiovascular Diseases
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Neurological Diseases
    • 8.9.1 Overview
    • 8.9.2 Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Other Therapeutic Applications
    • 8.10.1 Overview
    • 8.10.2 Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

  • 9.1 Overview
    • 9.1.1 North America: Biopharmaceuticals Market, by Country
      • 9.1.1.1 United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.1.2 United States: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.2 Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.2.2 Canada: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.3 Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. North America Biopharmaceuticals Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Amgen Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Eli Lilly and Co
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Bristol-Myers Squibb Co
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Johnson & Johnson
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Boehringer Ingelheim International GmbH
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Thermo Fisher Scientific Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 AGC Biologics AS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Lonza Group AG
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 WuXi Biologics Inc
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. United States Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. United States Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. United States Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. United States Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. United States Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. United States Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. United States Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. United States Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. United States Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. United States Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Canada Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Canada Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Canada Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Canada Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Canada Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Canada Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Canada Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Canada Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Canada Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Canada Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Mexico Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Mexico Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Mexico Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Mexico Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Mexico Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Mexico Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Mexico Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Mexico Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. Mexico Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. Mexico Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
  • Table 33. Recent Inorganic Growth Strategies in the North America biopharmaceuticals market
  • Table 34. Glossary of Terms

List Of Figures

  • Figure 1. North America Biopharmaceuticals Market Segmentation
  • Figure 2. North America Biopharmaceuticals Market, by Country
  • Figure 3. North America Biopharmaceuticals Market Overview
  • Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in North America Biopharmaceuticals Market
  • Figure 5. US Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. North America: PEST Analysis
  • Figure 7. Experts\' Opinion
  • Figure 8. North America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
  • Figure 9. North America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
  • Figure 10. North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • Figure 11. Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 42. Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Enterokinase: north America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 50. Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 51. Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 52. Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • Figure 54. Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 56. Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 58. Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 59. Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 61. Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. North America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 63. North America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  • Figure 64. United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 65. Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 66. Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)